[[Glioblastoma multiforme]] (GBM), an [[aggressive]] [[brain tumor]], is characterized histologically by the presence of a [[necrotic]] center surrounded by so-called[[ pseudopalisading cell]]s. [[Pseudopalisading necrosis]] has long been used as a prognostic feature. However, the underlying [[molecular]] mechanism regulating the progression of GBMs remains unclear. 

Wang et al., hypothesized that the [[gene expression profiling]]s of individual [[cancer]]s, specifically [[necrosis]]-related [[gene]]s, would provide objective information that would allow for the creation of a prognostic index. Gene expression profiles of necrotic and nonnecrotic [[area]]s were obtained from the [[Ivy Glioblastoma Atlas Project]] (IVY GAP) database to explore the differentially expressed genes.A robust signature of seven genes was identified as a predictor for glioblastoma and low-grade glioma (GBM/LGG) in patients from The [[Cancer Genome Atlas]] (TCGA) cohort. This set of genes was able to stratify GBM/LGG and GBM patients into high-risk and low-risk groups in the training set as well as the validation set. The TCGA, [[Repository for Molecular Brain Neoplasia Data]] ([[Rembrandt]]), and [[GSE16011]] databases were then used to validate the expression level of these seven genes in GBMs and LGGs. Finally, the differentially expressed genes (DEGs) in the high-risk and low-risk groups were subjected to [[gene ontology enrichment]], [[Kyoto Encyclopedia of Genes and Genomes]] pathway, and gene set enrichment analyses, and they revealed that these DEGs were associated with immune and inflammatory responses. In conclusion, the study identified a novel seven-gene signature that may guide the prognostic prediction and development of therapeutic applications
((Wang J, Ma J. Integrated Transcriptomic Analysis of Necrosis-related Gene in
Diffuse Gliomas. J Neurol Surg A Cent Eur Neurosurg. 2019 Apr 1. doi:
10.1055/s-0039-1683448. [Epub ahead of print] PubMed PMID: 30934097.
)).